February 03, 2026 13:06 ET | Source: Restem Initiation of the IIMPACT study follows promising Phase 1 results where Restem-L…
First in class study of an investigational ACTH receptor antagonist aims to address significant unmet need in children and adolescents…
SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…
June 06, 2025 16:07 ET | Source: Restem MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology…